IDH1 and glioblastoma: In fact, patients with MGMT-methylated glioblastomas achieve substantially longer median survival under standard therapy than those with unmethylated tumors.[18] Our results for IDH and MGMT status are in concordance with the literature and underscore why these biomarkers are now routinely tested, they provide critical prognostic information and guide therapy.